InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,362.00
(
-0.93%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.52
(
-0.02%
)
Bitcoin
66,487.52
(
1.06%
)
Post# of 252682
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120121
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 221320

Thursday, 06/20/2019 10:13:05 AM

Thursday, June 20, 2019 10:13:05 AM

Post# of 252682
ABUS starts phase-1 trial of AB-729 for HBV:

https://www.globenewswire.com/news-release/2019/06/20/1871749/0/en/Arbutus-receives-regulatory-clearance-to-initiate-Phase-1a-1b-Clinical-Trial-of-AB-729.html

AB-729 is an RNAi-based HBV-replication inhibitor; it should not be confused with AB-506, ABUS’ HBV “core” inhibitor that is already in phase-1 and will have an initial data readout this summer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up